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Abstract
The regulation of filopodia plays a crucial role during neuronal development and synaptogenesis. Axonal filopodia, which
are known to originate presynaptic specializations, are regulated in response to neurotrophic factors. The structural
components of filopodia are actin filaments, whose dynamics and organization are controlled by ensembles of actin-
binding proteins. How neurotrophic factors regulate these latter proteins remains, however, poorly defined. Here, using a
combination of mouse genetic, biochemical, and cell biological assays, we show that genetic removal of Eps8, an actin-
binding and regulatory protein enriched in the growth cones and developing processes of neurons, significantly augments
the number and density of vasodilator-stimulated phosphoprotein (VASP)-dependent axonal filopodia. The reintroduction
of Eps8 wild type (WT), but not an Eps8 capping-defective mutant, into primary hippocampal neurons restored axonal
filopodia to WT levels. We further show that the actin barbed-end capping activity of Eps8 is inhibited by brain-derived
neurotrophic factor (BDNF) treatment through MAPK-dependent phosphorylation of Eps8 residues S624 and T628.
Additionally, an Eps8 mutant, impaired in the MAPK target sites (S624A/T628A), displays increased association to actin-rich
structures, is resistant to BDNF-mediated release from microfilaments, and inhibits BDNF-induced filopodia. The opposite is
observed for a phosphomimetic Eps8 (S624E/T628E) mutant. Thus, collectively, our data identify Eps8 as a critical capping
protein in the regulation of axonal filopodia and delineate a molecular pathway by which BDNF, through MAPK-dependent
phosphorylation of Eps8, stimulates axonal filopodia formation, a process with crucial impacts on neuronal development
and synapse formation.
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Introduction
Deciphering the molecular mechanisms by which neurite
extension and synaptogenesis occur during brain development is
critical to understand the ontogenesis of the nervous system. In
addition, the knowledge of the mechanisms through which initial
synaptic contacts are established and modified during brain
development may also shed light on synaptic remodeling and
plasticity occurring in the adult brain. In the last years, evidence
has accumulated indicating that filopodia, which are highly motile,
narrow, cylindrical extensions emerging from both axons and
dendrites, play important roles at initial stages of synaptogenesis
[1,2]. Furthermore, the growth of new filopodia leading to new
synaptic contacts has been suggested as a possible mechanism
underlying long-term potentiation [1,3,4]. Although axonal
filopodia have been investigated less systematically, it is now well
established that filopodia extending at the tips of axonal growth
cones mediate neurite navigation and axonal path finding [5],
whereas filopodia emerging from the shaft of distal axonal
branches play a pivotal role in synapse formation [6]. Axonal
filopodia differ from both the growth cone and dendritic filopodia
since, in addition to bundles of filamentous actin, they also contain
clusters of synaptic vesicles that undergo exo-endocytotic recycling
[7–9]. These packages of vesicles move bidirectionally along the
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axonal shaft and the filopodia axis, and rapidly coalesce at the site
of contact with the appropriate target cell to generate mature
presynaptic sites [6,8]. Thus, filopodia emerging from axons are
destined to differentiate into future presynaptic sites.
The core structural and dynamic components of filopodia are
actin filaments, whose dynamic formation and topological
organization are controlled by ensembles of actin-binding proteins.
These proteins play different functional roles in regulating actin
dynamics, including binding and/or sequestering of actin
monomers, nucleation of actin filaments, capping or anticapping
of barbed ends, and severing, bundling, and anchoring of F-actin
(filamentous actin) [10–12]. In order to elongate, filopodia must be
protected from capping and becoming cross-linked into bundles
[13]. Formins, which promote the linear elongation of actin
filaments in a processive fashion, can also effectively compete with
cappers [14–16] and have therefore emerged as key players in the
generation of filopodia [13]. Alternatively, actin-binding proteins,
such as Ena/VASP family members, which bind barbed ends, and
bundle and elongate actin filaments [16–22], have also been
implicated in the formation and elongation of filopodia along
neurite shaft and growth cone [17,20,23,24]. Remarkably, mice
lacking all three Ena/VASP paralogs (ENA, MENA, and VASP)
have defective neuritogenesis in the cortex, leading to a block of
cortical axon-fiber tract formation. This defect was shown to arise
from a failure of cortical neurons to form filopodia [23]. The
neuritogenesis defect observed in Ena/MENA/VASP-deficient
cortical neurons could be rescued through intrinsic factors, such as
mDia2 or Myosin X, or extrinsic factors, such as laminin, that
induce filopodia formation [23]. Instead, no evidence has been
reported on the possible role of actin-capping proteins in
controlling the formation of axonal filopodia in neuronal cells.
Eps8 is the prototype of a family of proteins involved in the
transduction of signal from Ras to Rac, leading to actin
remodeling [25]. Eps8 directly controls actin dynamics and the
architecture of actin structures by capping barbed ends and cross-
linking actin filaments, respectively [26,27]. The barbed-end
capping activity of Eps8, which resides in its conserved C-terminal
effector domain, is tightly down-regulated within the context of the
holoprotein. Binding of Eps8 to one of its interactors, Abi1,
relieves this inhibition [28]. Conversely, Eps8 must associate with
IRSp53 (insulin receptor tyrosine kinases substrate of 53 kDa, also
known as BAIAP2 for binding partner of the brain-specific
angiogenesis inhibitor 1) [29–31] to efficiently cross-link actin
filaments [27]. These multiple actin regulatory roles of Eps8 in
vitro are reflected by the observation that in vivo Eps8 is required
for optimal actin-based motility, intestinal morphogenesis, and
filopodia-like extension [26–28]. The role of Eps8 in neuronal cells
is, however, still elusive.
Here, we show that Eps8 is enriched in the growth cone and
filopodia of developing hippocampal neurons, where it down-
regulates axonal filopodia formation through its barbed-end
capping activity. We also show that in vivo, the actin-capping
activity of the Eps8/Abi1 complex is modulated by MAPK-
mediated phosphorylation of the protein at the residues ser624
and thr628, which occurs in response to external cues, such as
BDNF, thereby explaining the induction of axonal filopodia by
BDNF treatment.
Results
Eps8 Controls the Formation of Axonal Filopodia via Its
Actin-Capping Activity
Eps8Ls family proteins are widely and concomitantly expressed
in most tissues in developing and adult mice [25]. The brain, in
which only the expression of Eps8 and Eps8L2, albeit at lower
levels, was detected, represents a notable exception [32]. This
prompted a more detailed analysis of the functional role of this
protein in neuronal cells.
In 3–4-d-old primary hippocampal cultures, we found Eps8
expressed in neuronal cell body and neurites, and prominently
enriched in the axonal growth cone (Figure 1A, arrow). In both rat
(Figure 1A–1C) and mouse (unpublished data) hippocampal
neurons, Eps8 was also detected along finger-like protrusions
emerging from the axonal shaft. These processes measured
3.27 mm60.07 standard error (SE) (in line with [33]), were highly
dynamic (Video S1), contained actin filaments (Figure 1B and 1D,
see also [7,9]) and the actin-binding proteins fascin (Figure 1C)
and VASP (Figure 1D), and were characterized by the presence of
synaptobrevin/VAMP2-positive vesicle clusters (Figure 2C and
2D, see also [8,9]), thus they are bona fide axonal filopodia.
Immunoblotting of subcellular fractions of fetal rat cortices
further indicated that Eps8 and its binding partner Abi1 were
concentrated in growth cone particles (GCPs) (Figure 1E), a
preparation that allows the investigation, using a biochemical
approach, of the expression and interaction of growth cone and
axonal proteins during neuronal development [34,35]. GCPs are
enriched in pinched-off, resealed, metabolically active growth
cones [34,35], as witnessed by the presence of the growth cone–
specific marker GAP43 and of actin [36,37]. Conversely, the
NMDA receptor subunit NR1, which is uniformly distributed in
the neuronal plasma membrane at this developmental stage [38],
is not enriched in the GCPs, whereas the proteolytic enzyme
cathepsin D, as expected, is excluded from this fraction, consistent
with its prevalent localization in the neuronal soma (Figure 1E).
To investigate the functional role of Eps8 in neuronal cells, we
established primary hippocampal cultures from eps8 WT and
deficient mice, and analyzed their morphology (Figure 1F–1I).
Strikingly, when compared to age-matched WT, eps82/2 neurons
displayed a significantly higher number of processes emerging
directly from the cell body (primary processes) (Figure 1G–1I).
Closer inspection of these cultures revealed that eps82/2 neurons
properly formed one single axon, positive for synaptobrevin/
VAMP2, which is sorted to the axon at early stages of neuronal
Author Summary
Neurons communicate with each other via specialized
cell–cell junctions called synapses. The proper formation of
synapses (‘‘synaptogenesis’’) is crucial to the development
of the nervous system, but the molecular pathways that
regulate this process are not fully understood. External
cues, such as brain-derived neurotrophic factor (BDNF),
trigger synaptogenesis by promoting the formation of
axonal filopodia, thin extensions projecting outward from
a growing axon. Filopodia are formed by elongation of
actin filaments, a process that is regulated by a complex
set of actin-binding proteins. Here, we reveal a novel
molecular circuit underlying BDNF-stimulated filopodia
formation through the regulated inhibition of actin-
capping factor activity. We show that the actin-capping
protein Eps8 down-regulates axonal filopodia formation in
neurons in the absence of neurotrophic factors. In
contrast, in the presence of BDNF, the kinase MAPK
becomes activated and phosphorylates Eps8, leading to
inhibition of its actin-capping function and stimulation of
filopodia formation. Our study, therefore, identifies actin-
capping factor inhibition as a critical step in axonal
filopodia formation and likely in new synapse formation.
Eps8 Regulates Axonal Filopodia Downstream BDNF
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development (Figure 2A and 2B). Conversely, a significantly
higher number of axonal filopodia was evident in eps8 null when
compared to control WT neurons (Figure 2A, 2A9, 2B, 2B9, and
2C, and Video S1). These protrusions contained synaptic vesicle
clusters (Figure 2C and 2D), were enriched in F-actin (Figure 2D
and 2E), were immunoreactive for fascin (Figure 2E), and were
significantly reduced by functional interference with VASP using a
dominant-negative approach [17] (Figure S1). Both the percentage
of neurons displaying filopodia emerging from the axons and the
density of axonal filopodia were increased by either genetic
(Figure 2F and 2G) or RNA interference (RNAi)-mediated
ablation of Eps8 (Figure S2A–S1E). On the other hand, no effect
on filopodia length was observed (unpublished data). Finally,
dendritic filopodia also were augmented in eps82/2 neurons at
early stages of dendrite formation (7 d in vitro [7DIV]) (Figures
S2F and S1G). Thus, Eps8 is critical for the proper extension of
neuronal filopodia, and its removal in neurons increases the
formation of axonal filopodia.
Next, we investigated whether the increase of axonal filopodia
in eps8 null neurons depends on the protein actin barbed-end
capping or cross-linking activity residing in its conserved carboxy-
terminal effector domain [27,28]. To this aim, we restored Eps8
expression in eps82/2 cultures with a lentiviral vector encoding
either a GFP-tagged Eps8 WT or an Eps8 mutant, Eps8MUT1,
specifically devoid of actin capping (Figure S3A), but retaining
actin-binding and -bundling activity (Figure S3B and S3C). The
infection of eps8 null neurons with the GFP-tagged Eps8 lentiviral
vector led to a significant reduction in the number of axonal
filopodia to WT levels (Figure 3A–3D). Thus, the filopodia
phenotype is specifically caused by the lack or reduction of Eps8.
Conversely, Eps8MUT1-infected neurons were morphologically
indistinguishable from GFP-infected cells (compare Figure 3F with
3G, see quantitation in Figure 3D) and retained an increased
number of axonal filopodia. It is of note that occasionally, and
especially at high levels of ectopic expression of WT Eps8, we
observed thick, sometimes club-like actin-based protrusions along
Figure 1. Eps8 is localized to sites of active actin polymerization in hippocampal neurons, and its removal increases neurite
number. (A–D) Eps8 localization in hippocampal neurons. Three days in vitro (3DIV) cultured hippocampal neurons were stained with anti-Eps8
antibody alone (A and A9) or in combination with either FITC-conjugated phalloidin to label F-actin (B), or anti-fascin (C) as indicated. The arrow in (A)
indicates the axonal growth cone. In the inset (A9), the arrowheads indicate axonal protrusions (arrowheads). The arrowheads indicate Eps8- and
actin- (B), or Eps8- and fascin-rich (C) filopodia protruding from the axon. (D) Actin rich axonal protrusions are also immunopositive for VASP. (E) Eps8,
its binding partner Abi1, and the growth cone markers GAP43 and actin, are enriched in preparations of growth cone particles (GCPs) relative to low-
speed supernatant brain homogenates (LSS). GCP preparations, described in Materials and Methods, were immunoblotted with the indicated
antibodies. The immunoblot is a representative example of five independent experiments. (F) Lysates from wild-type (WT) and eps82/2 (KO)
hippocampi were immunoblotted with anti-Eps8 antibody. Molecular weight markers are indicated. (G and H) Cultured hippocampal neurons (1DIV)
prepared from WT (G) or eps8 null (H) mice were fixed and stained with anti–beta-tubulin antibody. (I) Quantification of the number of neurites/
neuron. Hippocampal neurons were prepared as described in (G and H). The difference between the numbers of neurites of eps82/2 WT neurons is
statistically significant (Mann-Whitney rank sum test, p#0.001). Data are expressed as mean6standard deviation (SD); n= 897 examined WT neurons,
and 760 examined eps8 KO neurons. Bars indicate 5 mm for (A, B, C, and D); 3 mm for a9; and 10 mm for (G and H). Double asterisks (**) in (F and G)
indicate p,0.001.
doi:10.1371/journal.pbio.1000138.g001
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both axon and dendrites (Figure 3C and insert, Figure 3E), never
detectable in GFP-infected neurons, which showed a morpholog-
ical appearance comparable to eps82/2 neurons (Figure 3B, 3D,
and 3G). Collectively, these results support a critical role of the
barbed-end capping activity of Eps8 in regulating the balance
between different types of actin-based membrane extensions, and
more specifically, in controlling the formation of axonal filopodia
protrusions.
Eps8, to function as capper, requires the binding of its
interactors Abi1 or Abi2 [28]. Therefore, we analyzed the ability
of these latter proteins to form a complex with Eps8 in brain
lysates. Both Abi1 and the brain-specific Abi2 coimmunoprecipi-
tated with Eps8 (Figure S4A), indicating the existence of active
capping complexes and supporting the importance of the capping
activity in the nervous system. Conversely, in epithelioid HeLa
cells, no evidence of a complex between Abi1 or Abi2 and Eps8
could be found (Figure S4A), likely due to the fact that either Abi2
is expressed at lower levels than in brain (Figure S4A, right panel)
and/or these proteins are sequestered by interaction with other
partners. These latter findings suggest that the actin-capping
activity of Eps8 is critical for filopodia in neurons, but not in HeLa
cells, as previously shown [27].
Eps8 can form a complex with Abi1, Sos-1, and PI3K [39] able
to activate Rac, which, in turn, is involved in the formation of
neurites and filopodia-like processes in neurons [40] and is
activated by BDNF [41]. Thus, we examined the possibility that
the increase in axonal filopodia observed after genetic removal of
Eps8 could be due to reduced levels of Rac GTP. To this end, we
performed two sets of experiments. In the first approach, we
directly tested whether Eps8 removal impaired Rac activation.
Measurement of RacGTP levels by affinity-based CRIB assays
revealed that equal levels of RacGTP were present in lysates of
brain cortex and hippocampus derived from WT and eps8 null
mice (Figure S4B), indicating that in brain, Eps8 is not required for
Rac activation. As additional proof, the impairment of Rac
activation, which might be predicted to occur as a consequence of
Eps8 removal [42], was mimicked by exposing hippocampal
neurons to the specific Rac1 inhibitor, NSC23766 [43]. We
Figure 2. Genetic removal of eps8 causes increased number of axonal filopodia in hippocampal neurons. (A and B) Cultured
hippocampal neurons (3DIV) from WT and eps82/2 mice were fixed and stained with synaptobrevin/VAMP2 antibody. The selective sorting of
synaptobrevin/VAMP2 immunoreactivity to a single process reveals that only one neurite is the putative axon. Bar indicates 10 mm. (A9 and B9) Still
images of phase-contrast videos of the axonal shaft of cultured hippocampal neurons (3DIV) from WT and eps82/2 mice (see Video S1). Arrowheads
highlight axonal filopodia. (C) Representative examples of axonal shafts of WT and eps82/2 neurons, labeled with an antibody against synaptobrevin/
VAMP2. Bar indicates 10 mm. (D and E) Filopodia protruding from axons were costained with anti-synaptobrevin/VAMP2 antibody and phalloidin (D)
to detect synaptic vesicle and filamentous actin, respectively, or with anti-fascin and phalloidin (E), as indicated. Bar indicates 7 mm. (F and G) Neurons
from eps82/2 mice display a significantly higher density of axonal filopodia. (F) Quantification of the percentage of neurons with filopodia in WT and
eps82/2 neurons. Neurons with more than 0.04 filopodia/mm were considered as filopodia-bearing neurons (Student t-test, p#0.001). (G)
Quantification of the density of axonal filopodia in WT and eps8 null hippocampal neurons (Mann-Whitney rank sum test, p#0.001). n= 424 examined
WT neurons and 621 examined eps8 KO neurons. Data are expressed as the mean6SD.
doi:10.1371/journal.pbio.1000138.g002
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Figure 3. The regulation of filopodia density depends on Eps8 actin barbed-end capping activity. (A–D) Primary eps82/2 hippocampal
neurons (3DIV) were infected with either WT Eps8-EGFP (A and C) or control EGFP (B) lentiviral vectors, then fixed and processed for epifluorescence.
Neurons expressing Eps8 ([D] left top panel), but not those expressing EGFP ([D] left bottom panel), show a reduction in the density of axonal
filopodia ([D] right panel; number of examined neurons: 120 Eps8wt-EGFP, 55 EGFP; Kruskal-Wallis one-way analysis of variance, p,0.001) Data are
expressed as the mean6SEM. Of note, occasionally high levels of ectopically expressed Eps8 induced the presence of flattened structures, sometimes
with club-like endings, ([C] and inset in [E]). (E–G) Primary eps82/2 hippocampal neurons (3DIV) infected with either Eps8wt-EGFP (E) or Eps8MUT1-
EGFP (number of examined neurons: 31 [F]), an Eps8 mutant devoid of actin-capping activity (Figure S3), or control EGFP (G) lentiviral vectors were
fixed and processed for epifluorescence or stained with Texas Red phalloidin, as indicated. Merged images are also shown. Eps8MUT1 neurons do not
display flattened membrane protrusions and are morphologically undistinguishable from EGFP-infected neurons (see also quantitation [D], right
panel). Bar indicates 10 mm for (A, B, and C); 3 mm for the inset in (C), 5 mm for (D), and 8 mm for (E and G).
doi:10.1371/journal.pbio.1000138.g003
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demonstrated the efficacy of this compound by showing that
NSC23766 administration (1) prevented PDGF-induced actin
ruffles in NIH3T3 cells (Figure S4C), a well-known process
involving Rac activation [44], and (2) decreased RacGTP levels of
3DIV hippocampal cultures (Figure S4D). Notably, in hippocam-
pal neurons, a reduction rather than an increase in the number of
filopodia occurred upon Rac inhibition (Figure S4E), as previously
shown [45]. Thus, the pathways leading to Rac activation are not
the underlying molecular cause of the enhancement of axonal
filopodia extension observed in eps8 null hippocampal neurons
[45].
BDNF Induces Filopodia Formation via MAPK Activation
in Wild-Type, but Not eps82/2 Neurons
Having established a critical role for Eps8 capping activity in
down-regulating the formation of axonal filopodia, we next
investigated how Eps8 biological functions might be regulated in
vivo. Eps8 was originally isolated as a substrate of receptor tyrosine
kinases activated in response to growth factors [46]. Therefore, we
focused on the neurotrophic factor BDNF, which critically
controls growth and differentiation processes in the brain during
development, through the activation of Trk tyrosine kinase
receptors. Consistent with this, and as described previously [47],
treatment of hippocampal neurons with BDNF induced the
formation of axonal actin- and fascin-rich filopodia, mimicking
genetic and RNAi-mediated eps8 removal (Figure 4A and 4B).
Remarkably, however, the BDNF-induced increase in filopodia
density was not detected in eps82/2 cultures (Figure 4A and 4B).
Even if we cannot exclude the possibility that BDNF has no effect
on filopodia in eps82/2 neurons simply because the density of
filopodia is already maximal, this observation points to a role of
Eps8 in BDNF-mediated filopodia formation. BDNF induced, as
expected, MAPK activation in the GCPs (Figure 4C), and MAPK-
dependent phosphorylation of the synaptic vesicle protein synapsin
I [37], leading to its dispersion in the distal axonal shaft (Figure 4D)
[37,48]. More importantly, the formation of filopodia induced by
the neurotrophin was inhibited by pretreatment of the cultures
with the specific MAPK inhibitor, PD98059 (Figure 4E), indicat-
ing that MAPK activation is also critical in this pathway.
BDNF Controls the Subcellular Distribution of Eps8 via
MAPK Phosphorylation
One mechanism to control actin dynamics in response to
extracellular cues is to ensure the correct, spatially restricted
localization of critical actin-binding proteins, such as Eps8 and its
interactors. We thus examined the distribution of Eps8 to the
actin-rich, Triton X100–insoluble fraction of GCPs in response to
BDNF. Treatment with BDNF increased the amounts of Eps8
(Figure 4F) and, slightly, of its activator Abi1 (unpublished data),
recovered in the Triton X100–soluble fraction, causing a
reciprocal decrease in the Triton X100–insoluble fraction
(Figure 4F). Conversely, VASP was mainly found in the Triton-
insoluble fraction, and its distribution was unaffected by BDNF
stimulation (Figure 4F). Finally, Eps8 redistribution to the Triton
X100–soluble fraction correlated with BDNF-induced cellular
relocalization of Eps8, which disappeared from filopodia,
persisting instead along the axonal shaft, upon BDNF stimulation
(Figure 4G and quantification). Notably, both Eps8 redistribution
to the Triton-X100-soluble fraction and cellular relocalization by
BDNF were prevented by preincubation with the MAPK
inhibitor, PD98059 (Figure 4F and 4G). Thus, collectively, these
results indicate that BDNF controls, in a MAPK-dependent
manner, the dynamic cellular redistribution of Eps8 in vivo.
To investigate the molecular mechanisms through which BDNF
and MAPK regulate Eps8, its posttranslational modifications in
synaptosomes were analyzed by two-dimensional electrophoresis.
Seven Eps8 spots of similar molecular size, but different isoelectric
points (IP, Figure 5A, CTR), were detected by immunoblotting
with two independently raised antibodies (affinity-purified poly-
clonal antibody, Figure 5A; monoclonal antibody, unpublished
data), suggesting the existence of posttranslational modified forms
of Eps8. Competition of Eps8 monoclonal and polyclonal
antibodies with the respective immunogenic polypeptide further
validated the identity of the immunoreactive spots (unpublished
data). More importantly, treatment of synaptosomes with BDNF
induced a change in the electrophoretic pattern of Eps8 with the
appearance of additional spots of increased acidic IP (spots 6–9 in
Figure 5A, BDNF), which were significantly diminished by
pretreatment with MAPK inhibitor PD98059 prior to BDNF
stimulation (Figure 5A, PD+BDNF). Additionally, the five most
acidic spots of Eps8 could no longer be detected after
dephosphorylation of synaptosomes with alkaline phosphatase
(Figure 5A, BDNF+AP). Similar results were obtained in
preparations of GCPs (Figure 5B). Of note, Eps8 shows a different
electrophoretic pattern in untreated GCPs with respect to
untreated synaptosomes (Figure 5B, ‘‘CTR,’’ and 5A, ‘‘CTR’’),
suggesting that the protein is subjected to different posttransla-
tional modifications during brain development. Remarkably,
however, and at variance with stimulation with other RTK [46],
we could detect no Eps8 tyrosine phosphorylation after BDNF
treatment of synaptosomes (Figure S4F). Thus, collectively, the
above results support the notion that MAPK or a MAPK-
dependent distal kinase is responsible for Eps8 phosphorylation in
response to BDNF. To directly assess this possibility, we carried
out an in vitro phosphorylation assay. Purified Eps8 became
phosphorylated by recombinant purified MAPK to a similar
extent as a bona fide MAPK kinase substrate (myelin basic protein
[MBP]) (Figure 5C, first two lanes, and Figure S5A), thus
indicating that Eps8 is a direct substrate of activated MAPK.
Phosphorylation of S624 and T628 Controls the Barbed-
End Capping Activity of the Eps8:Abi1 Complex and Eps8
Subcellular Relocalization in Response to BDNF
To get insights into the residues specifically phosphorylated by
MAPK, a structure–function analysis was carried out using
different fragments of Eps8. Eps8 (586–733) is the minimal
fragment that is phosphorylated (Figure 5C). However, the lack of
phosphorylation of Eps8 (648–821) restricted further the phos-
phoresidue-containing region of Eps8 to amino acids 586–648.
This region contains two putative consensus sites (S624 and T628)
for MAPK (Prosite [49], Scansite [50]). Simultaneous mutation of
these sites to A (GST-535-821-SATA), either in the context of the
C-terminal 535–821 fragment of Eps8 (Figure 5D) or in the full-
length protein (Figure S5A), abrogated MAPK-mediated phos-
phorylation, unequivocally identifying the Eps8 residues targeted
by MAPK.
To demonstrate the biochemical and physiological relevance of
these phosphosites, we generated phosphoimpaired and phospho-
mimetic mutants of full-length Eps8 by substituting S624 and
T628 with either A (Eps8-SATA) or E (Eps8-SETE), respectively.
We initially tested the effects of these mutations using in vitro
assays of actin polymerization either in the context of the isolated
C-terminal, constitutive active Eps8 (535–821) fragment, or with
full-length Eps8 protein, whose activity is unmasked when in
complex with Abi1 [28]. We detected no difference in the affinities
for barbed ends when WT and Eps8 (535–821) mutants were
compared, suggesting that these phosphoresidues do not interfere
Eps8 Regulates Axonal Filopodia Downstream BDNF
PLoS Biology | www.plosbiology.org 6 June 2009 | Volume 7 | Issue 6 | e1000138
Figure 4. BDNF induces filopodia and regulates Eps8 intracellular localization through MAPK activation. (A and B) BDNF fails to
increase the number of filopodia in eps82/2 neurons. Wild-type (WT) and eps82/2 (KO) hippocampal neurons (3DIV) treated with BDNF (100 ng/ml for
20 min) or mock-treated (CTR), were fixed and stained to detect F-actin (B). Arrowheads highlight axonal filopodia. The density of filopodia was
calculated as in Figure 2F. Data are expressed as the mean6SD. Kruskal-Wallis one-way ANOVA on ranks, Dunn’s methods for comparison among
groups: there is a significant difference between ‘‘WT Ctr’’ and ‘‘WT BDNF’’ (p,0.05), whereas there is no difference among ‘‘WT BDNF’’, ‘‘eps8 KO Ctr,’’
and ‘‘eps8 KO BDNF’’ (p.0.05). (B) Example of axonal filopodia induced by BDNF in WT and eps82/2 hippocampal neurons fixed and stained as
described above. Bar indicates 5 mm. (C) Lysates of GCPs treated with BDNF (100 ng/ml for 20 min) were immunoblotted with the indicated
antibodies to detect phosphorylated MAPK and NR1 subunit of NMDA receptor, used as loading control. (D) Hippocampal neurons treated with BDNF
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Figure 5. Eps8 is phosphorylated by MAPK. (A) 2-D immunoblot analysis of Eps8 from synaptosomes mock-treated (CTR) or treated with BDNF
(BDNF) or pretreated with PD98059 before BDNF stimulation (PD+BDNF), or treated with BDNF followed by incubation with alkaline phosphatase
(BDNF+AP). Note the appearance, upon BDNF application, of additional and more intense Eps8 immunopositive spots with more acidic isoelectric
points (spots: 6–9). These spots disappear by preincubating synaptosomes with alkaline phosphatase. Insets show the analysis of synaptosomes
treated as above, resolved by monodimensional SDS-PAGE and immunoblotted with anti–phospho-MAPK (upper band) or anti-ribophorin (lower
band), the latter used as loading control. (B) 2-D immunoblot analysis of Eps8 in GCPs in the absence (CTR) or the presence of BDNF. (C) Recombinant
purified His-Eps8 (1–821) or recombinant GST-fused Eps8 fragments (5 mg) were incubated with 10 mCi [c-32P]-ATP in the presence (+) or absence (2)
of purified MAPK (20 ng) in kinase buffer (see Materials and Methods), resolved by SDS-PAGE, stained with Coomassie Blue (lower panel), and
subjected to autoradiography (upper panel). The red arrow indicates the shift of Eps8 due to phosphorylation. (D) Recombinant purified GST-Eps8
535–821 wild-type (WT) or S624A, T628A (SATA) mutant (5 mg) were incubated with 10 mCi [c-32P]-ATP in the presence (+) or absence (2) of purified
MAPK (20 ng) in kinase buffer (MB), resolved by SDS-PAGE, stained with Coomassie Blue (lower panel) and subjected to autoradiography (upper
panel). In (C and D), MBP (myelin basic protein) was used as a control substrate.
doi:10.1371/journal.pbio.1000138.g005
(100 ng/ml for 20 min) (BDNF) or mock-treated (CTR) were stained with anti-Synapsin I antibody (Syn). Bar indicates 2 mm. (E) Hippocampal neurons
were incubated with PD98059 or vehicle as control, and treated with BDNF (100 ng/ml for 20 min) (BDNF) or mock-treated (CTR). Cells were fixed and
processed as above. Neurons with axonal filopodia (neurons with more than 0.04 filopodia/mm were considered as positive) were quantified. BDNF
treatment almost doubles the percentage of neurons with filopodia, whereas pretreatment with PD98059 prevents this effect (one-way ANOVA, post
hoc Tukey test, double asterisks [**] indicate p#0.001). Data are expressed as the mean6SD. (F) GCPs treated (BDNF) or not (CTR) with BDNF, prior or
not PD98059 exposure, were fractionated using 1% Triton X100. Triton X100–soluble (sol) and -insoluble (ins) fractions were immunoblotted with the
indicated antibodies. Synaptotagmin I (Stg) and tubulin were used as controls. Right graph: quantification of the Eps8 distribution to Triton X100–
soluble fraction was performed by densitometry and normalized using synaptotagmin I (one-way ANOVA, post hoc Tukey test, p#0.001). (G) Left:
vehicle or PD98059-incubated hippocampal neurons (3DIV) were mock-treated or treated for 20 min with 100 ng/ml BDNF, as indicated. Cells were
fixed and stained with anti-Eps8 antibody (red) and FITC-phalloidin to detect F-actin (green). Merged images are shown. Note that Eps8
immunoreactivity is virtually lost from filopodia upon BDNF treatment and that PD98059 prevents this relocalization. Right graph: quantitation of
Eps8 fluorescence intensity measured in filopodia and axonal shafts under the different experimental conditions. Error bars represent SEM.
Quantitation has been carried out by ImageJ software on 30 images from three independent experiments, filopodia are identified by labeling with
phalloidin (one-way ANOVA, p,0.001 in filopodia and p.0.05 in axonal shaft). Bar indicates 5 mm. Note that Eps8 immunoreactivity is significantly
reduced from filopodia upon BDNF treatment, and restored by PD98059.
doi:10.1371/journal.pbio.1000138.g004
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with the direct binding of the isolated Eps8 capping domain to
actin barbed ends (Figure S5B and S5C). Of note, phosphorylation
of S624 and T628 did not affect the actin filaments side-binding
capacity of Eps8 (Figure S5D and S5E). Thus, when Eps8 C-
terminal fragments are folded into a presumably ‘‘open’’
conformation that allows its association to actin barbed ends and
filaments, we could evidence no detectable effects of its
phosphorylation. Conversely, the affinity of the Eps8-SETE:Abi1
complex for actin filament barbed ends was about 10 times lower
that of the Eps8-WT:Abi1 or EPS8-SATA:Abi1 complexes
(Figure 6A–6C). Importantly, Eps8-SATA and -SETE bound
Abi1 with similar affinities as Eps8WT (Figure 6D). Thus,
phosphorylation of Eps8 significantly impaired the actin-capping
activity of Eps8:Abi1 complex, most likely by facilitating Abi1’s
ability to promote the structural changes required to activate Eps8.
Next, we tested whether these posttranslational modifications of
Eps8 had any effect on Eps8 distribution, association to actin-
based structures, or BDNF-mediated relocalization. Remarkably,
we found that in neuronal cells, Eps8-SATA was distributed to and
colocalized with discrete actin-rich structures (Figure 7A), whereas
Eps8-SETE showed a more diffuse distribution (Figure 7B), in line
with the hypothesis that the latter, phosphomimetic construct is
constitutively detached from actin filaments. Additionally, and
more importantly, WT Eps8 (Figure 7C), but not Eps8-SATA
(Figure 7D), was dispersed after BDNF stimulation. This is
consistent with the possibility that, being unable to be phosphor-
ylated, Eps8-SATA does not detach from actin even after BDNF
treatment. Finally, the expression of Eps8-SATA (Figure 7D and
7G), but not Eps8-SETE (Figure 7E), significantly inhibited the
formation of BDNF-induced axonal filopodia (Figure 7G), acting
Figure 6. The phosphomimetic Eps8 (Eps8-SETE) mutant has a 10-fold reduced barbed-end capping activity with respect to Eps8
WT or phosphoimpaired Eps8 (Eps8-SATA) mutant when in complex with Abi1. (A) The indicated, increasing concentrations of equimolar
amounts of purified His–Eps8 WT, SATA, and SETE (Eps8, SATA, and SETE) and GST-Abi1 were incubated with 2.5 mM G-actin (10% pyrenyl-labeled) in
polymerization buffer. Actin polymerization was initiated by spectrin–actin seeds as described in Materials and Methods. GST was used as a control.
(B) The relative inhibition of barbed-end polymerization rate at the indicated concentrations of the Eps8-WT:Abi1, Eps8-SATA:Abi1, and Eps8-
SETE:Abi1 complexes is shown. Under suboptimal, nonsaturating conditions (100 nM concentrations), the Eps8-SETE:Abi1 complex is less effective in
inhibiting barbed-end growth than Eps8 WT or Eps8-SATA:Abi1 complexes. Three independent experiments were performed. Error bars indicate SEM.
(C) The relative inhibition of barbed-end polymerization at the various, indicated concentrations of the WT Eps8:Abi1 or Eps8-SETE:Abi1 complexes.
The concentrations of Eps8-WT:Abi1 and Eps8-SETE:Abi1 at which half-maximal inhibition (IC50) was observed were 60 and 200 nM, respectively,
which correspond to a concentration of the respective complexes of: Eps8(WT):Abi1 = 0.15 nM; Eps8-SETE:Abi1 = 1.5 nM (based on calculated
thermodynamic constant of association between Eps8 and Abi1 (Kd = 35 mM [72]). The data shown are representative of four independent
experiments with similar results. (D) Eps8 phosphomutants bind Abi1 similar to Eps8 WT. Lysates of cells expressing GFP-Eps8 WT or SATA or SETE
(indicated at the top) were incubated with immobilized GST, or GST-PIN1, used as negative control, or GST-Abi1 (asterisk [*] in the figure). The lower
bands on the GST-Abi1 lanes are likely premature termination or degradative products of the Abi1 moiety of the fusion protein. Lysates and bound
proteins were immunoblotted with the indicated antibodies (on the right). IVB, in vitro bound.
doi:10.1371/journal.pbio.1000138.g006
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Figure 7. Eps8-SATA is preferentially localized along actin-rich structures and inhibits BDNF-induced filopodia. (A and B)
Hippocampal neurons (3DIV) were transfected by calcium phosphate with GFP-Eps8-SATA (A), GFP-Eps8-SETE (B) and examined 20 h after
transfection. Cells were fixed and stained with TRITC phalloidin (red) and processed for epifluorescence to detect F-actin and Eps8 (green),
respectively. Merged images are shown. Bar indicates 5 mm. (C–E) BDNF induces dispersion of WT Eps8, but not of Eps8-SATA or Eps8-SETE.
Hippocampal neurons (3DIV) transfected with GFP-Eps8-WT (C), GFP-Eps8-SATA (D), or GFP-Eps8-SETE (E) were examined 20 h after transfection,
upon stimulation with 100 ng/ml BDNF (BDNF) or mock-treatment (CTR). Cells were fixed and processed for epifluorescence as described above. Bar
indicates 10 mm in the upper panels and 5 mm in the magnified axons shown in the lower panels. (F) Quantification of the density of filopodia in
cultured hippocampal neurons (3DIV) transfected with GFP-Eps8-WT (n= 26) or GFP-Eps8-SATA (n=34) and analyzed 20 h after transfection, either
untreated or upon 20-min exposure to BDNF (100 ng/ml). Data are expressed as the mean6SD (Student t-test, double asterisks [**] indicate
p#0.001).
doi:10.1371/journal.pbio.1000138.g007
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in a dominant fashion. Collectively, these data indicate that
phosphorylation of S624, T628 residues controls the barbed-end
capping activity of the Eps8:Abi1 complex and Eps8 subcellular
localization in response to BDNF. Thus, one mechanism to
activate the protrusive activity by BDNF in neurons is to down-
modulate the activity of capping proteins, via MAPK phosphor-
ylation, favoring actin filament elongation and axonal filopodia
extensions.
Discussion
In this study, we demonstrated through genetic and cellular
biochemical approaches, a crucial role of the actin barbed-end
capping activity of Eps8 in down-regulating the formation of
VASP-dependent neuronal filopodia. We further show that this
activity is controlled by phosphorylation of residues S624 and
T628 of Eps8, which occurs upon MAPK activation in response to
BDNF, thus unraveling the molecular components of a novel
signaling cascade converging on a capping protein and ultimately
leading to the proper formation of axonal filopodia.
Filopodia are formed by cross-linked actin filaments, whose
initiation is controlled by the balance between capping and
anticapping activities. Anticapping activity can be executed either
by formins, which promote linear elongation of actin filaments
from barbed ends competing with cappers, or by Ena/VASP
proteins, albeit through multiple and diverse biochemical
mechanisms. Indeed, VASP family proteins may directly [17,18]
or indirectly antagonize capping proteins [22], capture barbed
ends [51], and cross-link actin filaments [20,22]. Formins and
Ena/VASP family proteins act independently of each other, as
demonstrated by the finding that genetic removal of Ena, MENA,
and VASP abrogates filopodia, which, however, can be restored
by expression of the formin mDia2 [23]. Thus, there are likely
multiple and independent mechanisms that give rise to filopodia.
This is reflected by the fact that different models have been
proposed to account for the initiation and elongation of filopodia
with respect to other protrusions, such as lamellipodia. For
instance, the convergent elongation model [52] proposes that the
Arp2/3-dependent dendritic nucleation of actin filaments is the
starting point of actin filament arrays in both lamellipodia and
filopodia. The activity of capping proteins, according to this
model, is then crucial to control the subsequent architectural
organization of actin in these protrusions. When the capping
activity is high, newly nucleated branched filaments become
rapidly capped. The balance between de novo branched
nucleation and elongation by Arp2/3 and blockade of filament
growth by capping proteins, both competing for filament ends,
would thus result in the generation of a dendritic actin network at
the leading edge of lamellipodia. In this context, it is remarkable
that Eps8, when expressed at high levels, causes the formation of
flat, actin-rich protrusions along axons, which resemble lamelli-
podia extensions (Figure 3). Conversely, when capping activity is
low, such as after RNAi-mediated interference or genetic
knockdown of Eps8 in neurons, filaments nucleated by Arp2/3
[53] can grow longer, uncapped. Factors such as VASP family
members or components of the filopodia tip complex may then
promote the transient association of actin filaments, which can be
further stabilized by other cross-linkers, such as fascin, thus
permitting the formation of bundles of sufficient stiffness to
overcome buckling and membrane resilience [54]. Of note,
filopodia initiation, rather than elongation, is affected by Eps8.
A corollary of this model is that Eps8-dependent filopodia should
be, at least in part, mediated by VASP. Consistently, we show here
that the increased axonal filopodia of eps8 null hippocampal
neurons are significantly reduced upon interference of VASP
functions through dominant-negative approaches, suggesting
functional competition between the capping activity of Eps8 and
the actin-regulatory properties of VASP. This is reminiscent of a
situation similar to the one suggested by Mejillano and colleagues
in nonneuronal cells, where depletion of the capping protein CP
caused loss of lamellipodia and the explosive formation of
filopodia, a phenotype which is counteracted by Ena/VASP
proteins [21].
An alternative model of filopodia initiation questioned the
relevance of Arp2/3-mediated nucleation (reviewed in [13]),
claiming instead that linear filament elongation at the leading edge
of protrusions is the source of bundles in filopodia. Within this
context, formins [16,55–57] or clustered VASP proteins [22] may
be the culprits in promoting filopodia initiation. Also in this case,
however, filaments must be protected from cappers, which have
been shown, in the case of CP, to compete, either directly or
indirectly, with VASP as well as with formins for barbed-end
binding. Whether Eps8 can compete with clustered VASP or
formins for barbed ends remains to be assessed. The fact that
filopodia induced by removal of Eps8 are dependent on VASP
argues, however, that a balanced activity of these two proteins may
be critical for proper axonal filopodia formation.
Notably, Eps8 is a multifunctional protein, whose actin-related
activities, capping and bundling, are critically controlled by its
binding partners, Abi1 and IRSp53, respectively [27,28]. Both
capping and bundling activities need to be coordinated and
regulated for the initiation and maintenance of filopodia. In
neurons, in which Eps8 is tightly bound to Abi1 or Abi2, the
capping function prevails, exerting a negative modulatory role on
filopodia extension. Conversely, in HeLa cells, where the majority
of Eps8 is associated with IRSp53 [27], and no complex with Abi1
or Abi2 is detected, the Eps8:IRSp53 complex bundles actin
filaments, positively contributing to the formation of filopodia.
Thus, specific patterns of protein expression and different Eps8-
based complexes may be the basis of the different roles that this
protein exerts in different experimental systems.
One of the major accomplishments of our study is the
demonstration that extracellular cues regulate the subcellular
localization and function of Eps8 through phosphorylation. This
mode of regulation defines a novel mechanism through which
signaling cascades, particularly those emanating from receptor
tyrosine kinases, may regulate cappers. Indeed, how the activity of
capping proteins is controlled in a signaling-dependent manner
has remained a critical, only partially addressed issue. Phospho-
inositides, whose generation is controlled through the balance of
signaling-regulated lipid kinases and phosphates, can bind and
inhibit both gelsolin and CP [58,59]. Albeit recent evidence
obtained using yeast CP questioned whether phosphatidylinositol
3,4-bisphosphate (PIP2) can access CP when it is bound to ends
[60], thus casting doubts that this lipid may effectively free barbed
ends from capping. Protein:protein interaction is another way to
control the activity of capping proteins. In this respect, Carmil, an
adaptor protein, was shown to bind CP with high affinity and to
inhibit capping, influencing the formation of lamellipodia [61].
Conversely, Abi1 functions as an activator of the otherwise
inhibited Eps8.
We show here that BDNF, in particular, controls the barbed-
end capping activity of the Eps8:Abi1 complex and modulates
Eps8 interaction with the cytoskeleton, strengthening the impor-
tance of spatially restricted activation of proteins in the regulation
of actin dynamics. Accordingly, BDNF-mediated detachment of
Eps8 from actin cytoskeleton correlates with increased filopodia
formation, which can be mimicked by genetic removal of this
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capper. At the molecular level, this is achieved through MAPK-
mediated phosphorylation of Eps8 residues S624 and T628, which
controls the protein capping activity, with a 10-fold reduction in
barbed-end binding of the Eps8:Abi1 complex, following S624
and T628 phosphorylation. Since Eps8 localization depends on
both binding to Abi1 [62] and to actin, this reduction in actin
binding reasonably contributes to Eps8 subcellular relocalization
in response to BDNF. Of note, BDNF-induced detachment of
Eps8 from cytoskeletal structures is not accompanied by that of
VASP, which remains enriched in the Triton-insoluble fraction,
where it may more efficiently associate to filament ends,
promoting their elongation.
The regulation of actin-capping activity of Eps8 may have
consequences for the developing and adult brain. It is now widely
accepted that presynaptic specializations, which are highly dynamic
and are continuously added and eliminated throughout the lifetime
of a neuron, play an active role in activity-dependent synapse
formation and remodeling. In the mature neocortex in vivo, for
example, filopodia and short axonal branches are frequently
extended and retracted to form boutons onto postsynaptic structures,
or to originate en-passant boutons, which are added and eliminated
along the axonal shaft (reviewed in [63]). Notably, eps8 null brains, at
early postnatal stages, display a significantly higher number of
presynaptic boutons (unpublished data) that might originate from the
increased axonal filopodia during neuronal development, thus
suggesting a role of the protein in controlling synapse formation in
vivo. The dynamic regulation of eps8 actin-capping activity may
therefore play an important role in presynaptic plasticity phenomena
in the developing brain and, possibly, in the adult brain.
Materials and Methods
Expression Vectors, Reagents, and Antibodies
Cytomegalovirus (CMV) promoter–based and elongation fac-
tor-1 (EF1)-promoter–based eukaryotic expression vectors and
GST bacterial expression vectors were generated by recombinant
PCR.
Polyclonal and monoclonal antibodies (abs) against Eps8 and
Abi1 were previously described [42,64]. Monoclonal abs against
synaptobrevin/VAMP2, synaptophysin, SNAP-25, NR1, and
synaptotagmin I were from Synaptic System. Monoclonal abs
against Gap43, actin, phosphorylated ERK1,2, and beta-tubulin
were purchased from Sigma. Monoclonal ab against phosphory-
lated JNK was from New England Biolab. Polyclonal ab against
synapsin I was a kind gift from P. De Camilli (Yale University), ab
against riboforin was from G. Kreibich (New York University),
and ab against human cathepsin D was from C. Isidoro (Universita`
di Novara). Antibody against fascin was from Dako: clone 55K-2.
Antibody against VASP was from BD Transduction Laboratories
or from Dr. F. Gertler. GST-VASP was a gift from Dr. C. Le
Clainche (CNRS, Gif-sur-Yvette, France). Mouse monoclonal
anti-IRSp53 were raised against full-length histidine-tagged
recombinantly purified proteins.
FITC-phalloidin and Texas Red phalloidin were purchased
from Sigma and Molecular Probes, respectively. The secondary
abs conjugated to FITC, Rhodamine, or horse radish peroxidase
were obtained from Jackson Immunoresearch Laboratories.
Recombinant human BDNF was obtained from Regeneron.
PD98059 is from Sigma.
NSC23766 is a kind gift from Y. Zheng (Cincinnati Children’s
Hospital Medical Center)
Shrimp Alkaline Phosphatase was from Roche Diagnostics.
Monoclonal anti-pY, activated Erk1, and purified MBP were
purchased from Upstate.
The Eps8 S624A, T628A (SATA), and S624E, T628E (SETE)
mutants were generated by PCR (SATA 1861-TCT GCC CCA
(TR G)CA CCC CCT CCA (ARG)CG CCA GCA CCC-1893;
SETE 1861-TCT GCC CCA (TCRGA)A CCC CCT CCA
(ACR GA)G CCA GCA CCC-1893).
Animal Experiment
The Eps8-KO mice obtained as previously described [42] were
backcrossed for more than ten generations to C57BL/6 mice. For
preparation of hippocampal culture, littermates derived from
heterozygous crosses were used; in some experiments, WT and
knockout (KO) mice from F2N12 homozygous colonies were also
used. All experiments were performed in accordance with the
guidelines established in the IFOM-IEO Campus Principles of
Laboratory Animal Care (directive 86/609/EEC).
Hippocampal Cell Cultures
Primary neuronal cultures were prepared from the hippocampi
of 18-d-old fetal rats as described [65] or E16-P1 WT and eps8 null
mice. The dissociated cells were plated onto glass coverslips coated
with poly-L-lysine at densities ranging from 10,000 to 20,000 cells/
cm2. After a few hours, the coverslips were transferred to dishes
containing a monolayer of cortical glial cells. The cells were
maintained in MEM (Gibco) without sera, supplemented with N2
(Gibco), 2 mM glutamine, and 1 mg/ml BSA (neuronal medium).
Small RNA Interference
Three different double-strand small interfering RNA (siRNA)
oligonucleotides (Stealth RNAi; called 1525, 1526, and 1158) were
designed against mouse eps8 by using RNAi Design Services from
Invitrogen. Oligonucleotide sequences:
1525: 59-GCCATGCCTTTCAAGTCAACTCCTA-39;
1526: 59-CCATGCCTTTCAAGTCAACTCCTAA-39;
1158: 59-GACAAAAGACACAGTTGATTTCTTAA-39.
Stealth RNAi negative control with medium content of CG
(Invitrogen) whose sequence is not homologous to any vertebrate
sequence/transcriptome was used as control. WT mouse hippo-
campal neurons were transfected with Lipofectamine 2000
(Invitrogen) and with each oligonucleotide sequence at the dose
of 200 nM the day of plating, fixed at 3DIV, and stained with anti-
VAMP2 abs and phalloidin to evaluate filopodia density.
Lentiviral Vectors and Lentiviral Infection
GFP alone or GFP-eps8 WT or eps8MUT1 were subcloned in a
pRRLsin.PPT.CMV lentiviral vector (kind gift of L. Naldini, San
Raffaele, Milano). The 293T human embryonic kidney cells were
cotransfected with the lentiviral vector and the packaging plasmids
(pMDL, pRev, and pVSVG), providing the required trans-acting
factors, namely, Gag-Pol, Rev, and the envelope protein VSVG,
respectively, and viruses were obtained as described [66]. Primary
cultures established from eps82/2 mice were infected 1 d after
plating with GFP/GFP-Eps8/GFP-Eps8-MUT1 lentiviruses. Me-
dium was changed after 6 h of incubation, and cells were fixed
48 h after viral infection.
Immunocytochemistry
The cultures were fixed and stained as previously described
[38]. The images were acquired using a BioRad MRC-1024
confocal microscope equipped with LaserSharp 3.2 software.
Image Analysis and Statistics
Acquired images were analyzed using Metamorph Imaging
Series 6.1 software (Universal Imaging). The number of filopodia
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and the length of axonal shaft were then computed in order to obtain
the filopodia density (number of filopodia/micrometer). For each
neuron, an axon length ranging between 30 and 80 mm was
analyzed. Alternatively, the percentage of neurons with filopodia was
evaluated. In this latter case, neurons with more than 0.04 filopodia/
mm were considered as filopodia-bearing neurons. For each
experimental condition, both types of analyses gave similar results.
Statistical analysis was performed using SigmaStat 2.0 software
(Jandel Scientific). After testing whether data were normally
distributed or not, the appropriate statistical test has been used.
Detailed information is reported in the figure legends. Statistical
significance is indicated in graphs as follows: a single asterisk (*)
indicates p,0.05; double asterisks (**), p,0.001.
Biochemical Techniques
Growth cone particles. GCPs were prepared as described
[35,36]. Isolated GCPs were diluted in seven to eight volumes of
modified Krebs Ringer solution (180 mM sucrose, 50 mM NaCl2,
5 mM KCl, 22 mM Hepes (pH 7.4), 10 mM glucose, 1.2 mM
NaH2PO4, 1.2 mM MgCl) containing, if needed, an antagonist
(PD98059 30 mM) and kept on ice for 5 min. For stimulation,
GCPs were transferred to 37uC for 5–10 min, then an agonist
(BDNF 100 ng/ml) was added for 20 min. A fraction of GCP was
immediately resuspended in SDS containing sample buffer for
analysis of phosphoproteins. The remaining sample was extracted
in 1% Triton X-100 for 10 min on ice and subsequently
centrifuged for 1 h at 100,000g. Both pellet (TX-100–insoluble
fraction) and supernatant (TX-100–soluble fraction) were
processed by SDS gel electrophoresis followed by western blotting.
Synaptosome preparation. The purification of
synaptosomes from rat forebrain was carried out as described
[67]. Samples with a protein content of 200 mg were pelleted and
resuspended in KRH devoid of Ca2+, but containing PD98059 if
needed. The samples were kept for 10 min on ice and then
transferred for 10 min to 37uC. After addition of BDNF, they were
left for 10 min at 37uC, then a fraction corresponding to 50 mg of
protein was mixed with SDS containing sample buffer for
phosphoprotein analysis. The remaining sample was processed
for two-dimensional gel electrophoresis (2DE).
Two-dimensional gel electrophoresis. Immobilized pH
gradient (IPG) gel strips (pH 3–10 nonlinear [NL], 7 cm; General
Electric Healthcare) were used as the first-dimension gel of 2DE
for isoelectric focusing. GCPs (ca. 250 mg) or synaptosomes
(125 mg) were solubilized overnight on a rotating wheel at 4uC
by adding 6.4 volumes of distilled water with 1% TritonW-100
f.c.(final concentration) and protease inhibitor cocktail (Sigma;
1:1,000 f.c.), Phosphatase Inhibitor Cocktail I and II (Sigma;
1:1,000 f.c.) and desoxyribonuclease 10 mg/ml. Proteins were then
precipitated with cold acetone to a final concentration of 80%.
The pellet obtained was resuspended in 125 ml of rehydration
buffer containing 7 M urea, 2 M thiourea, 2% Triton, 2% chaps,
1% IPG buffer ampholyte (pH 3–10 NL; General Electric
Healthcare), 50 mM DTT, and a trace amount of bromophenol
blue; gels rehydrated and subjected to isoelectric focusing at 18uC
with a stepwise-increased voltage (rehydration 0 V for 1 h; 30 V
for 12 h; 500 V for 1 h; 1,000 V for 1.5 h; 5,000 V for
24,000 V6h). After the first dimensional electrophoresis, the
strips were incubated in equilibration buffer (50 mM Tris-HCl
[pH 6.8], 6 M urea, 30% glycerol, 2% SDS) with 20 mg/ml DTT
for 20 min, followed by 20 min in equilibration buffer with
25 mg/ml iodoacetamide, and resolved in 8% SDS-
polyacrylamide mini gels as second dimensional electrophoresis.
Protein dephosphorylation with alkaline phospha-
tase. Dephosphorylation of Eps8 was investigated by treatment
with alkaline phosphatase (AP). For this experiment, BDNF-treated
synaptosomes (ca 125 mg) were solubilized in adequate volume of
dephosphorylation buffer (1%Triton-X100, 50 mMTRIS [pH 8.0],
1 mM MgCl2, 1 mM EDTA) with protease inhibitor cocktail
(1:1,000 f.c.) and desoxyribonuclease 10 mg/ml on a rotating wheel
at 4uC overnight. Then synaptosomes were centrifuged for 30 min at
16,000 rpm in a refrigerated microcentrifuge (Eppendorf). The
supernatant was treated with 20 units of AP for 1 h at 37uC. After,
samples were processed as usual for 2DE by adding 6.4 volumes of
distilled water with 1% TritonW-100 f.c. and protease inhibitor
cocktail (Sigma, 1:1,000 f.c.), and desoxyribonuclease 10 mg/ml, and
proteins were precipitated with four volumes of cold acetone.
Cell fractionation. HeLa cells were transfected with the
indicated expression vectors using Lipofectamine (Invitrogen),
according to the manufacturer’s instructions. One day after
transfection, cells were collected and counted. An equal number of
cells were lysed in TX buffer (15 mM Hepes [pH 7.2], 80 mM
NaCl, 2 mM MgCl2, 0.1% Triton X-100, protease inhibitor
cocktail [Roche]). After 10 min on ice, cells lysates were subjected
to ultracentrifugation (145,000g, 45 min, 4uC). Supernatants
corresponded to the Triton X-100–soluble, cytosolic-enriched
fractions; pellets were solubilized in equal volumes of RIPA buffer
(15 mM Hepes [pH 7.2], 140 mM NaCl, 3 mM MgCl2, 1 mM
EDTA, 0.5% sodium deoxycholate, 1% NP-40, 2% SDS, protease
inhibitor cocktail [Roche]), subjected to extensive sonication, and
centrifuged at 16,000g for 20 min at 4uC. Supernatants
represented the Triton X-100–insoluble, membrane- and F-
actin–enriched fractions. Equal amounts of each fraction were
loaded, resolved on SDS-PAGE, and immunoblotted with the
appropriate antibodies. Biochemical fractionation experiments
were performed at least three times unless otherwise indicated.
Eps8 purification. His-Eps8 FL WT, SATA, or SETE were
purified from human 293T cells. Briefly, 293T cells transfected
with pCDNA-HisMax4-Eps8s were lysed in 20 mM phosphate
buffer (pH 8.0), 500 mM NaCl, 20 mM imidazole, 1 mM b-
mercapto-ethanol, 5% glycerol, protease inhibitor cocktail (Roche)
and sonicated. His-Eps8s were purified using Ni-NTA-agarose
(Qiagen) following standard procedures. Recombinant Eps8
fragments were expressed as GST fusion proteins in the BL21
Escherichia coli strain (Stratagene), and affinity purified using GS4B
glutathione–sepharose beads (Amersham Pharmacia Biotech).
Eluted proteins were dialysed in 50 mM Tris-HCl, 150 mM
NaCl, 1 mM DTT, and 20% glycerol.
In vitro phosphorylation assay. Purified His-Eps8, Eps8
GST-fragments or MBP (Upstate) were incubated with 10 mM [c-
32P]-ATP (Amersham Pharmacia Biotech) in kinase buffer
(20 mM Tris HCl [pH 7.5], 10 mM orthovanadate, 10 mM
MgCl2, 50 mM NaCl, 1 mM DTT, 1 mM NaF) in the presence
or absence of purified MAP Kinase 1/Erk1, active (Upstate) for
30 min at 30uC. Phosphorylation of the Eps8 GST fragments used
in actin polymerization assays was as follow: GST Eps8 535–821
was incubated in the presence of an excess of cold ATP (10 mM)
with or without MAPK.
Actin polymerization assays. Actin cosedimentation assays
were performed as described [28]. Briefly, monomeric rabbit G-
actin was induced to polymerize at 30uC in F-actin buffer (5 mM
Tris-HCl [pH 7.8], 0.2 mM ATP, 1 mM DTT, 0.1 mM CaCl2,
1 mM MgCl2, and 100 mM KCl). Recombinant and purified
GST-fusion proteins or control buffer were subsequently
incubated with F-actin and ultracentrifuged for 30 min at
400,000g in a Beckman TL-100 table-top ultracentrifuge. Equal
amounts of starting materials, supernatants, and pellets were
solubilized in loading buffer, boiled, and then resolved on an SDS–
PAGE gel together with standards of actin and Eps8 proteins.
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Actin polymerization was monitored by the increase in
fluorescence of 10% pyrenyl-labeled actin. Seeded polymerization
was induced by addition of 0.1 M KCl, 1 mM MgCl2 and
0.2 mM EGTA to a solution of Ca-ATP–G-actin (2.5 mM)
containing spectrin–actin seeds (0.25 nM) and the desired amount
of recombinant proteins. Fluorescence measurements were
performed at 20uC in a Safas Sfx or a Spex Fluorolog 2
spectrofluorimeter. The initial rate of barbed-end growth was
measured. The affinity for barbed ends was derived as described in
[28].
Actin bundling assays were performed as described in [27].
Crib assays for Rac activation. The levels of Rac-GTP
were measured by affinity precipitation using GST-CRIB (Cdc42
and Rac interactive region) of PAK1, as described in [42]. In brief,
cells or tissues were lysed in buffer containing 50 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 10 mMMgCl2, 1% NP-40, 5% glycerol,
and 1 mM EDTA (pH 8), 1 mM PMSF, and Protease Inhibitor
Cocktail Set III (Calbiochem). Lysates were incubated with 30 mg
of GST-CRIB protein immobilized on glutathione-Sepharose
(AmershamBiosciences) beads, for 1 h at 4uC. Specifically bound
GTP-Rac was detected by immunoblot with anti-Rac1.
Supporting Information
Figure S1 Functional interference of VASP significantly
reduces the number of axonal filopodia in eps8 null
neurons. Left panel, 3DIV eps82/2 hippocampal neurons
expressing FPPPmitoGFP [17] or GFP as control (green) were
stained with anti-VASP antibody (blue) and Texas Red phalloidin
(red). Expression of FPPPmitoGFP, which displaces VASP from its
normal sites of localization, sequestering it to the mitochondrial
surface, heavily decreases the number of filopodia protruding from
the axon (right graph, Mann-Whitney rank sum test, p,0.001).
Arrowhead points to a not-transfected process bearing filopodia.
Bar indicates 6 mm for (E).
Found at: doi:10.1371/journal.pbio.1000138.s001 (5.13 MB EPS)
Figure S2 Down-regulation of Eps8 by siRNA or genetic
approaches promotes the formation of neuronal filopo-
dia. (A–F) Down-regulation of Eps8 by siRNA effectively reduced
protein levels in NIH3T3 cells and hippocampal neurons, where it
leads to increased filopodia density. (A and B) Lysates of NIH3T3
cells transfected with three different siRNA oligonucleotides
against Eps8 (1525, 1226, and 1158) or a scramble oligo (CTR)
were immunoblotted with anti-Eps8 or anti-tubulin, as a loading
control, antibodies. (B and C) The efficacy of the oligonucleotide
1525 to down-regulate Eps8 expression is shown in NIH3T3 cells
(B) and primary hippocampal neurons (C) by immunofluorescence
with an anti-Eps8 antibody. Similar results were obtained using
the other two oligos (unpublished data). Asterisks in (B) indicate
the nucleus of RNAi oligo-transfected cells. Bars indicate 10 mm.
(D) Examples of axonal shafts from scrambled, control (CTR)- and
1525-transfected neurons stained for synaptobrevin/VAMP2. Bar
indicates 6 mm. (E) Quantification of the density of filopodia of
cultured hippocampal neurons (3DIV), untransfected (unt) or
transfected with a scrambled oligonucleotide (scrbld), or with the
three oligonucleotides against Eps8. (Kruskal-Wallis one-way
analysis of variance [ANOVA] on ranks, p#0.001). Data are
expressed as the mean6SE. (F and G) Genetic removal of eps8
causes increased number of dendritic filopodia in hippocampal
neurons. (G) WT and eps82/2 hippocampal neurons were
transfected with EGFP and examined at 7DIV. Dendritic filopodia
are visualized by EGFP fluorescence. (H) Quantification of the
density of dendritic filopodia in WT and eps8 null hippocampal
neurons (Mann-Whitney rank sum test, p,0.001). Bars indicate
12 mm for low-magnification images, and 8 mm for high-
magnification images.
Found at: doi:10.1371/journal.pbio.1000138.s002 (6.23 MB TIF)
Figure S3 Biochemical characterization of Eps8MUT1.
(A) Eps8MUT1 lacks barbed-end capping. Kinetics of actin
polymerization induced by spectrin–actin seeds in the presence of
GST-Eps8 648–821 (250 nM) or GST-Eps8 648-821 MUT1 (250
nM) bearing three point mutations (V729A, T731A, and W733A).
Fluorescence was monitored over time. Whereas Eps8-648-821
completely inhibits actin polymerization at substoichiometric
concentrations with a constant of dissociation for barbed ends of
Kd = 4 nM (unpublished data), as previously reported [28], Eps8-
648-821 MUT1 displays no significant barbed-end capping
activity, as indicated by its constant of dissociation for barbed
ends, which is 1,000-fold higher thaN Eps8 648-821 (Kd = 4,000
nM, unpublished data), while retaining filament binding and cross-
linking activity (see below). (B). Eps8MUT1 binds to actin
filaments, such as Eps8, in ultracentrifugation assays. GST-Eps8
648–821 or GST-Eps8 648–821 MUT1 (GST-MUT1) were
incubated either alone (2) or in the presence (+) of the indicated
concentrations of F-actin and subjected to ultracentrifugation.
Pellets and supernatants were immunoblotted with the indicated
abs. The amounts of F-actin in pellet and supernatant in absence
of GST fusion proteins were also determined. (C) Eps8MUT1
cross-links actin filaments. Filamentous actin (1 mM) was incubat-
ed either in the presence of GST (left panel) or the indicated
concentration of GST-Eps8 648–821 or GST-Eps8 648–821
MUT1 (GST-MUT1). The reaction mixture was incubated at
room temperature for 30 min. Actin was then labeled with
rhodamine-phalloidin, and DABCO 0.1% and methyl cellulose
0.1% were added to the mixture. The samples were mounted
between a slide and a coverslip coated with poly-lysine and imaged
by fluorescence microscopy. Bar indicates 2 mm. The rationale to
engineer the three mutations (V729A, T731A, and W733A) stems
from the following set of observations: we found that the eps8
capping domains display sequence, secondary, and tertiary
structure similarity with the SAM Pointed (SAM_PNT) domain,
which belong to the larger family of sterile alpha motif (SAM) [68].
The recently solved nuclear magnetic resonance (NMR) structure
of the C-terminal region of human EPS8L2 (residues 612–697,
1WWU), a member of the EPS8L family protein [25], and of
human EPS8 (residues 699–784, 2E8M) deposited in the Protein
Data Bank (PDB) database, fully confirmed this assertion. This
domain is composed of five consecutive alpha helices, from N- to
C-terminus, named alpha1 to alpha5. We previously reported
through structure-function analysis using various Eps8 fragments
that the one encompassing amino acids (aa) 674–737 and
including the two first alpha helices is sufficient to mediate actin
capping [28], but loses actin bundling [27], indicating that the
integrity of these helices is critical for capping. We thus mutated
three residues predicted on the basis of secondary structures and
the NMR data to disrupt zand thus to hamper capping, but not
bundling. We verified these predictions experimentally as
described above. A detailed structural and biochemical analysis
of Eps8 mode of capping actin filaments is currently on-going and
will be described elsewhere.
Found at: doi:10.1371/journal.pbio.1000138.s003 (3.76 MB EPS)
Figure S4 Contribution of Abi1 and Abi2 (A), rac
activation (B–E), and tyrosine phosphorylation (F) to
Eps8 function. (A) Abi1 and Abi2 coimmunoprecipitate with
Eps8 in brain lysates, but not in HeLa cells. Left panels: total
lysates from either brain cortex and hippocampi (3 mg) (H/C) or
HeLa cells were immunoprecipitated as indicated on top. Lysates
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(50 mg) and immunoprecipitates were analyzed by immunoblot-
ting with the indicated antibodies. Right panel: equal amounts of
cell lysates from HeLa cells or mouse primary hippocampal
neurons (Hip) were immunoblotted with the indicated antibodies
to analyze the relative expression levels of Eps8 and its binding
partners (Abi1, Abi2, and IRSp53). The different electrophoretic
pattern of IRSp53 between HeLa and hippocampi reflects the
existence of multiple splice variants differentially expressed in
different tissues [69–71]. (B–E) Eps8 removal causes increased
filopodia in a Rac-independent manner. Eps8 removal does not
impair RacGTP levels in brain. (B) The levels of RacGTP in brain
cortex and hippocampus derived from WT and eps82/2 mice are
similar. Equal amounts of total tissue protein extract from brains
of adult wild-type (WT) or eps82/2 (KO) littermates were
incubated in the presence of GST-fused Pak1-CRIB (Cdc42 and
Rac interactive binding motif). Lysates from total tissue protein
extract (lower panel, Rac) and GST-CRIB (upper panel, RacGTP)
bound proteins were immunoblotted with anti-Rac antibodies. (C
and D) Efficacy of the Rac inhibitor NSC23766 in mouse embryo
fibroblasts and in hippocampal neurons. (C) Serum-starved
NIH3T3 cells were incubated with NSC23766 (50 mM) or vehicle
(mock) for 48 h before addition of PDGF(100 ng/ml for 7 min) or
mock treatment. Cells were then fixed and labeled with FITC-
phalloidin. The Rac1 inhibitor NSC23766 completely abrogates
actin ruffles induced by PDGF. (D) Levels of RacGTP in
hippocampal cultures (3DIV) upon exposure to 50 mM
NSC23766 for 3 h determined by affinity CRIB-based assay as
described in (B). (E) Quantification of filopodia density in
hippocampal neurons (3DIV) treated with NSC23766 (50 mM
for 3 h); the histogram shows the normalized mean number of
axonal filopodia per micronmeter (Mann-Whitney rank sum test,
p#0.001). Data are the mean6SE. Bar indicates 20 mm. (F)
BDNF stimulation does not induce Eps8 tyrosine phosphorylation.
Pellets from rat forebrain synaptosomes preparations (1 mg, see
Materials and Methods) mock-treated (2) or treated with BDNF
(+) 100 ng/ml 20 min, where resuspended in 50 mM HEPES
(pH 7.5), 1% glycerol, 50 mM NaCl, 1% Triton X-100, 1.5 mM
MgCl2, 5 mM EGTA, protease inhibitor cocktail (Sigma, 1:1000
f.c.), phosphatase inhibitor cocktail I and II (Sigma, 1:1000 f.c.) at
4uC and subjected to immunoprecipitation with anti-Eps8 (Eps8)
or control antibody (CTR). Immunoprecipitates (IPs) and control
lysates (Inputs) were resolved by SDS-gel electrophoresis and
immunoblotted (IB) with the indicated antibodies.
Found at: doi:10.1371/journal.pbio. 1000138.s004 (4.25 MB TIF)
Figure S5 Biochemical characterization of Eps8 phos-
phomutants. (A) Eps8-SATA is not phosphorylated by MAPK.
Recombinant purified His-Eps8 WT or His-Eps8-SATA (3 mg)
were incubated with 10 mCi [c-32P]-ATP in the presence (+) or
absence (2) of purified MAPK (20 ng) in kinase buffer (see
Materials and Methods). MBP (myelin basic protein) was used as
positive control of the reaction. Products were analyzed by SDS-
PAGE followed by autoradiography (right panels). The red arrow
indicates the shift of Eps8 due to phosphorylation. Left panel
shows Coumassie Blue staining analysis of recombinant MBP and
Eps8. MAPK-mediated phosphorylation does not affect the
barbed-end capping activity of the isolated C-terminal Eps8
535–821 fragment. (B and C) Actin polymerization assay of WT or
mutated Eps8 capping domain in the presence of MAPK. (B)
Either 5 or 100 nM of Eps8 C-terminal fragment (535–821)
phosphorylated by MAPK (P-535) in the presence of an excess of
ATP (see Materials and Methods) or Eps8 C-terminal fragments
preincubated with only MAPK (535+M) or ATP (535+A) as
controls, were mixed to MgATP-G-actin (2.5 mM, 10% pyrenyl-
labeled) and 0.25 nM of spectrin–actin seeds. Fluorescence was
monitored over time. (C) Phosphomutants of Eps8 (535–821) display
similar affinity to barbed ends as Eps8 WT. Increasing amounts of
purified Eps8 WT, SATA, or SETE mutant C-terminal regions
(535–821 WT, 535–821 SATA, and 535–821 SETE) were mixed to
MgATP–G-actin (2.5 mM, 10% pyrenyl-labeled) and 0.25 nM of
spectrin–actin seeds. Fluorescence was monitored over time. The
relative inhibition of polymerization rate, calculated as described in
the Materials and Methods section, was plotted over different
concentrations of Eps8 fragments. The affinity for actin barbed ends
of each of the Eps8 C-terminal fragments is shown. (D) MAPK-
mediated phosphorylation does not affect the binding of Eps8 (535–
821) to F-actin. Eps8 C-terminal fragment (GST-535-821) (1 mM)
incubated with MAPK in the presence or absence of an excess of
ATP (see Materials and Methods) were mixed with 5 mM of F-actin
and subjected to cosedimentation assay by high-speed ultracentri-
fugation. Each lane shows the supernatant (S) and the pellet (P) after
ultracentrifugation. (E) Phosphomutants of Eps8 (535–821) display
similar binding ability to F-actin as Eps8 WT. Equal molar amounts
(1 mM) of Eps8 WT, or SATA or SETE C-terminal fragments
(GST-535-821) were incubated either alone or with 5 mM (upper
panel) or 2 mM (lower panel) of F-actin and subjected to
cosedimentation assay by high-speed ultracentrifugation. Each lane
shows the supernatant (S) and the pellet (P) after ultracentrifugation.
Found at: doi:10.1371/journal.pbio.1000138.s005 (4.27 MB TIF)
Video S1 The dynamic formation of axonal filopodia is
significantly increased in eps82/2 as compared to WT
hippocampal neurons. Hippocampal neurons (3DIV) were
obtained from E18 WT (top) and eps8 null (bottom) mice. The
dissociated cells were plated onto glass coverslips coated with poly-
L-lysine at densities ranging from 10,000 to 20,000 cells/cm2. After
a few hours, the coverslips were transferred to dishes containing a
monolayer of cortical glial cells. Live imaging recording was
performed by Zeiss LSM 510 Meta. Frames were taken every 5 s
for a total of 4 min. Bar indicates 10 mm. Insets show a magnified
detail of filopodia dynamically emerging and retracting from the
axonal shaft. It is evident from these movies that the average
length of filopodia (3.660.8 standard error of the mean [SEM],
n=50) is not significantly affected by removal of Eps8, which
instead causes an increase in the number of cell-forming filopodia
and in the density of filopodia along the axon. This suggests that
the capping activity of Eps8 likely regulates initiation rather than
elongation of filopodia. Additionally, expression of high levels of
ectopic eps8 blocks the formation of filopodia rather than
preventing their elongation (Figure 3).
Found at: doi:10.1371/journal.pbio.1000138.s006 (2.77 MB
MOV)
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